Brief: Medincell: Phase 3 Data Of mdc-IRM Shows Significant Improvements In Patients With Schizophrenia

Medincell SA

01/11/2021 06:55

Nov 1 (Reuters) - Medincell SA  MEDCL.PA :
    * PHASE 3 DATA OF MDC-IRM, FIRST PRODUCT BASED ON
MEDINCELL’S
TECHNOLOGY, SHOWS SIGNIFICANT IMPROVEMENTS IN PATIENTS WITH
SCHIZOPHRENIA
    * ONGOING NEW DRUG APPLICATION REVIEW BY FDA COULD LEAD TO
COMMERCIALIZATION AS EARLY AS 2022 IN U.S. BY TEVA
    * IS ELIGIBLE FOR DEVELOPMENT AND COMMERCIAL MILESTONES
($122
MILLION), AND ROYALTIES ON NET SALES

Source text for Eikon:  ID:nBw392zksa 
Further company coverage:  MEDCL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))